Subscribe to RSS
Download PDF
DOI: 10.1055/s-0038-1651899
Studies on the Biochemistry of Urokinase
Publication History
Publication Date:
04 July 2018 (online)
Summary
Direct evidence for an active center histidine residue in urokinase (UK) was obtained with use of newly synthesized peptide chloroketones Ac-Gly-Lys-CH2C1 and Nle-Gly-Lys-CH2C1. Stoichiometric inactivation by DFP provided further evidence that UK is a serine protease. Essential histidine and serine residues were both located in the heavy chain of the 47,0 M. W.UK. The high M.W. form can be converted (catalytically) to the low M. W. form.
9 partially purified human urinary UK preparations (5 with predominantly high M. W. UK), varying in purity and proportion of high and low M. W. forms, were found to be heterogeneous by a number of acrylamide electrophoretic procedures. 7 preparations had strikingly similar molar activities at excess substrate, except for the lower values found in 2 predominantly high M. W. UK preparations from the same supplier. 2 high M. W. UK preparations from another supplier showed a definite increase in activity when assayed at low plasminogen concentration, but this effect was abolished after gel filtration (Sephadex G-25), by further purification with affinity chromatography, or when assayed with excess plasminogen.
The high and low M. W. forms of UK (47,000 and 33,400 M. W.), isolated and purified by Sepharose-EACA-agmatine affinity chromatography were shown to be homogeneous by Coomassie Blue staining after SDS-polyacrylamide gel electrophoresis (PAGE) and by 14C-DFP and 14C-NPGB incorporation before SDS-PAGE. Comparative properties of the high M. W. vs low M. W. forms were as follows: specific activity (104,000 IU/mg vs 226,000) ; 2 chains (33,100 and 18,600 M.W.) linked by disulfide(s) vs a single chain; pi 8.60 (major subform) and pi 8.90 (minor subform) vs pi 8.35, 8.60, 8.70 (major subform) and pi 8.05 (minor subform); and second order kinetics for DFP inactivation (400 vs 770 M−1 min−1). The molar activities were similar (9.6 × 109 and 10.2 × 109IUm/mole) for each form.
-
References
- 1 Ball A. P, Day E. D. 1970; Immunological identification of two urokinases. Thrombosis et Diathesis Haemorrhagica 24: 463.
- 2 Ball A. P, Silver D, Day E. D. 1971; Plasminogen-fibrinogen complex formation as a prelude to fibrinogenolysis. Thrombosis et Diathesis Haemorrhagica 24: 114.
- 3 Barlow G, Lazer L, Reuter A, Tribby T. 1977. Production of plasminogen activator by tissue culture techniques. In: Thrombosis and Urokinase. Paoletti R, Sherry S. (eds.) Academic Press; New York.:
- 4 Burges R. A, Brammer K. W, Coombes J. D. 1965; Molecular weight of urokinase. Nature 208: 894.
- 5 Doleschel W, Auerswald W. 1967; Determination of molecular weight uroprotein fractions with urokinase activity by means of molecular sieving. Med. Pharmacol. Exper 16: 225.
- 6 Fahrney D. E, Gold A. M. 1963; Sulfonylfluorides as inhibitors of esterases. Journal of the American Chemical Society 85: 997.
- 7 Geratz J. D. 1970; Inhibition of the thrombin, plasmin and plasminogen activators by amidino compounds. Thrombosis et Diathesis Haemorrhagica 23: 486.
- 8 Geratz J. D. 1971; Inhibition of coagulation and fibrinolysis by aromatic amidine compounds. Thrombosis et Diathesis Haemorrhagica 25: 391.
- 9 Groskopf W. R, Hsieh B, Summaria L, Robbins K. C. 1969; Studies on the active center of human plasmin. Journal of Biological Chemistry 224: 359.
- 10 Holmberg L, Bladh B, Astedt B. 1976; Purification of urokinase by affinity chromatography. Biochimica et biophysica acta 445: 215.
- 11 Johnson A. J, McCarty W. R. 1959; The lysis of artificially induced intravascular clots in man by intravenous infusions of streptokinase. Journal of Clinical Investigation 38: 1627.
- 12 Kakkar V. V, Sagar S, Lewis M. 1975; Treatment of deep-vein thrombosis with intermittent streptokinase and plasminogen infusion. Lancet II: 674.
- 13 Kok P, Astrup T. 1969; Isolation and purification of tissue plasminogen activator and its comparison with urokinase. Biochemistry 8: 79.
- 14 Landmann H. 1973; Studies on the mechanism of action of synthetic antifibrinolytics. Thrombosis et Diathesis Haemorrhagica 29: 253.
- 15 Landmann H, Markwardt F. 1970; Irreversible synthetische Inhibitoren der Urokinase. Experientia 26: 145.
- 16 Lesuk A, Terminiello L, Traver J. H. 1965; Crystalline human urokinase: some properties. Science 147: 880.
- 17 Magnusson S, Hartley B. S. 1972. In: Atlas of Protein Sequence and Structure. Dayhoff M. O. (ed.). Vol. 5, D-109 The National Biomedical Research Foundation; Silver Spring, Md.:
- 18 Ong E. B, Johnson A. J. 1976; a Protamine, a substrate for thrombolytic agents and enzymes of similar specificity. Analytical Biochemistry 75: 568.
- 19 Ong E. B, Johnson A. J, Schoellmann G. 1976; b Identification of an active site histidine in urokinase. Biochimica et biophysica acta 429: 252.
- 20 Ong E. B, Soberano M. E, Johnson A. J. 1977; Influence of substrate on urokinase assay results, (abstract). Federation Proceedings 36: 288.
- 21 Petkov D, Christova E, Pojarlief I, Stambolieva N. 1975; Structure activity relationships in the urokinase hydrolysis of N-acetyl-L-lysine anilides. Eur. J. Biochem 51: 25.
- 22 Robbins K. C, Summaria L, Hsieh B, Shah R. J. 1967; The peptide chains of human plasmin; mechanism of activation of human plasminogen to plasmin. Journal of Biological Chemistry 242: 2333.
- 23 Sharp A. A. 1975. Mechanism of fibrinolysis. In: Progress in Chemical Fibrinolysis and Thrombolysis. (eds.) Davidson J. F, Samana M. M, Desnoyers P. C. New York, New York: Raven Press; Vol. 1. 19.
- 24 Sherry S, Alkjaersig N, Fletcher A. P. 1964; Assay of urokinase preparation with the synthetic substrate acetyl-L-lysine methyl ester. Journal of Laboratory and Clinical Medicine 64: 145.
- 25 Sherry S, Fletcher A. P, Alkjaersig N. 1959; Fibrinolysis and fibrinolytic activity in man. Physiological Reviews 39: 343.
- 26 Soberano M.E, Ong E. B, Johnson A. J. 1976; a The effects of inhibitors on the catalytic conversion of urokinase. Thrombosis Research 9: 675.
- 27 Soberano M. E, Ong E. B, Johnson A. J, Levy M, Schoellmann G. 1976; b Purification and characterization of two forms of urokinase. Biochimica et biophysica acta 445: 763.
- 28 Soberano M. E, Ong E. B, Johnson A. J, Schoellmann G, Levy M. 1975; Inhibition studies of urokinase with diisopropylphosphorofluoridate (DFP) and p-nitrophenyl-p’guanidinobenzoate (NPGB) (abstract). Federation Proceedings 36: 288.
- 29 Thorsen S. 1975; Differences in the binding to fibrin of native plasminogen and plasminogen modified by proteolytic degradation; influence of ω-amino-carboxylic acids. Biochimica et biophysica acta 393: 55.
- 30 Thorsen S, Glas-Greenwalt P, Astrup T. 1972; Differences in the binding to fibrin of urokinase and tissue plasminogen activator. Thrombosis et Diathesis Haemorrhagica 28: 65.
- 31 Walasek O. F. 1975; Isolation and studies of the multimolecular forms of urinary urokinase, (abstract). Federation Proceedings 34: 677.
- 32 Wallen P, Wiman B. 1975 Purification of tissue activator using affinity adsorption on fibrin and hydrophobic interaction chromatography; effect of fibrin on the enzymatic properties of the activator. Proc. Vth. Inti. Congr. Thromb. Haemos.. 348.
- 33 Walton P. L. 1967; The hydrolysis of a-N-acetylglycyl-L-lysine methyl ester by urokinase. Biochimica et biophysica acta 132: 104.
- 34 White W. F, Barlow G. H, Mozen M. 1966; The isolation and characterization of plasminogen activators (urokinase) from human urine. Biochemistry 5: 2160.
- 35 Wiman B, Wallen P. 1977; The specific interaction between plasminogen and fibrin; a physiological role of the lysine binding site in plasminogen. Thrombosis Research 1: 213.